B
104.12
1.76 (1.72%)
| 前收盘价格 | 102.36 |
| 收盘价格 | 102.74 |
| 成交量 | 5,353,528 |
| 平均成交量 (3个月) | 8,294,590 |
| 市值 | 154,040,336,384 |
| 市盈率 (P/E TTM) | 76.00 |
| 预期市盈率 (P/E Forward) | 35.84 |
| 价格/销量 (P/S) | 8.85 |
| 股市价格/股市净资产 (P/B) | 6.95 |
| 52周波幅 | |
| 利润日期 | 22 Jul 2025 - 28 Jul 2025 |
| 营业毛利率 | 11.58% |
| 营业利益率 (TTM) | 20.09% |
| 稀释每股收益 (EPS TTM) | 1.37 |
| 季度收入增长率 (YOY) | 20.90% |
| 季度盈利增长率 (YOY) | 36.20% |
| 总债务/股东权益 (D/E MRQ) | 52.16% |
| 流动比率 (MRQ) | 1.45 |
| 营业现金流 (OCF TTM) | 3.81 B |
| 杠杆自由现金流 (LFCF TTM) | 2.32 B |
| 资产报酬率 (ROA TTM) | 5.28% |
| 股东权益报酬率 (ROE TTM) | 9.50% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Medical Devices (US) | 看跌 | 混合的 |
| Medical Devices (全球的) | 看跌 | 混合的 | |
| 股票 | Boston Scientific Corporation | 混合的 | 看涨 |
AIStockmoo 评分
0.5
| 分析师共识 | 2.0 |
| 内部交易活动 | -1.5 |
| 价格波动 | -0.5 |
| 技术平均移动指标 | 0.0 |
| 技术振荡指标 | 2.5 |
| 平均 | 0.50 |
|
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales. |
|
| 部门 | Healthcare |
| 行业 | Medical Devices |
| 投资方式 | Large Core |
| 内部持股比例 | 0.18% |
| 机构持股比例 | 93.22% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Bollard Group Llc | 31 Mar 2025 | 20,490,826 |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 125.00 (Citigroup, 20.05%) | 购买 |
| 125.00 (Morgan Stanley, 20.05%) | 购买 | |
| 125.00 (Barclays, 20.05%) | 购买 | |
| 中 | 120.00 (15.25%) | |
| 低 | 112.00 (Evercore ISI Group, 7.57%) | 购买 |
| 平均值 | 119.67 (14.94%) | |
| 总计 | 9 购买 | |
| 平均价格@调整类型 | 102.56 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| Leerink Partners | 16 Jun 2025 | 118.00 (13.33%) | 购买 | 101.49 |
| Needham | 28 May 2025 | 115.00 (10.45%) | 购买 | 104.51 |
| 24 Apr 2025 | 115.00 (10.45%) | 购买 | 101.14 | |
| Citigroup | 22 May 2025 | 125.00 (20.05%) | 购买 | 104.50 |
| Morgan Stanley | 16 May 2025 | 125.00 (20.05%) | 购买 | 106.04 |
| Barclays | 25 Apr 2025 | 125.00 (20.05%) | 购买 | 101.90 |
| Baird | 24 Apr 2025 | 120.00 (15.25%) | 购买 | 101.14 |
| Evercore ISI Group | 24 Apr 2025 | 112.00 (7.57%) | 购买 | 101.14 |
| RBC Capital | 24 Apr 2025 | 120.00 (15.25%) | 购买 | 101.14 |
| Truist Securities | 24 Apr 2025 | 117.00 (12.37%) | 购买 | 101.14 |
| 名称 | 平均购买 ($) | 平均卖出 ($) | 总净额 | 总净值 ($) |
|---|---|---|---|---|
| BROWN VANCE R | - | 104.78 | -1,952 | -204,531 |
| FITZGERALD JOSEPH MICHAEL | - | 104.78 | -50,000 | -5,239,000 |
| 累积净数量 | -51,952 | |||
| 累积净值 ($) | -5,443,531 | |||
| 累积平均购买 ($) | - | |||
| 累积平均卖出 ($) | 104.78 | |||
| 名称 | 持有人 | 日期 | 类型 | 数量 | 价格 | 价值 ($) |
|---|---|---|---|---|---|---|
| BROWN VANCE R | 职员 | 01 Jul 2025 | 处理 (-) | 1,952 | 104.78 | 204,531 |
| BROWN VANCE R | 职员 | 01 Jul 2025 | 执行期权 | 4,036 | - | - |
| FITZGERALD JOSEPH MICHAEL | 职员 | 01 Jul 2025 | 自动卖出 (-) | 50,000 | 104.78 | 5,239,000 |
| FITZGERALD JOSEPH MICHAEL | 职员 | 01 Jul 2025 | 执行期权 | 50,000 | - | - |
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合